CA-A Cancer Journal for Clinicians

Papers
(The TQCC of CA-A Cancer Journal for Clinicians is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Minority groups underrepresented in hematologic cancer trials13683
Evolution of community outreach and engagement at National Cancer Institute‐Designated Cancer Centers, an evolving journey12066
Cancer treatment and survivorship statistics, 20258667
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies5093
1896
Issue Information1751
Near majority of adults favor R ratings for films with smoking1471
Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer681
Highlighting American Cancer Society‐funded research in CA: A Cancer Journal for Clinicians464
Cancer statistics 2024: All hands on deck427
Most patients with cancer are not undergoing germline genetic testing351
Multicancer detection tests: What we know and what we don’t know288
Current treatment and future directions in the management of anal cancer278
Breast cancer: The good, the bad, and an important call to effective risk reduction strategies272
Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types270
More care needed for cancer caregivers268
266
Issue Information233
Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial180
Clinical practice guideline and expert consensus recommendations for rehabilitation among children with cancer: A systematic review176
Underrepresentation of Hispanic women in science, technology, engineering, mathematics, and medicine158
The evolving landscape of tissue‐agnostic therapies in precision oncology154
Health insurance status and cancer stage at diagnosis and survival in the United States152
Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians145
Does distance deter male fertility preservation?142
Medicaid expansion increases survival for patients with cancer135
Study identifies risk factors that may lead to secondary cancers133
Overlooked barriers to implementation of geriatric assessment126
Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma112
Lung cancer screening guidelines: Smoking matters, not quitting100
The contemporary management of cancers of the sinonasal tract in adults92
Interventional gastroenterology in oncology85
Cancer survivors at greater risk for bone fractures late in life79
Issue Information70
Bilateral mastectomy may not reduce mortality risk68
Issue Information68
Screening for lung cancer68
Breast Cancer Statistics, 202266
From medical student to Editor: A note of thanks66
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance62
Prevention of device‐related infections in patients with cancer: Current practice and future horizons59
Issue Information59
Clinical management of metastatic colorectal cancer in the era of precision medicine57
American Cancer Society nutrition and physical activity guideline for cancer survivors54
Cancer treatment and survivorship statistics, 202253
53
Better communication is key for quality‐of‐life improvement in low‐income and minority patients53
Issue Information51
37
Cancer misinformation on social media37
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries33
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors33
Key issues face AI deployment in cancer care32
29
26
Fecal microbiota transplants may aid melanoma immunotherapy resistance26
Social determinants of health and US cancer screening interventions: A systematic review26
Immunotherapy combination shows longer progression‐free survival than chemotherapy alone for patients with a rare type of metastatic colorectal cancer26
0.051981925964355